<DOC>
	<DOC>NCT02211261</DOC>
	<brief_summary>A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Men and women of nonchildbearing potential with Type 2 Diabetes Mellitus Subjects on stable doses of metformin &gt;/= 1500 mg daily (SAD cohorts) or &gt;/= 1000 mg daily (MAD cohorts) x 30 days prior to screening HbA1c 710% (SAD Cohorts) or 6.510% (MAD cohorts) inclusive at screening Fasting Cpeptide &gt;1.12 ng/mL (SAD cohorts) or &gt;/= 0.8 mg/mL (MAD cohorts) at screening History of Type 1 diabetes mellitus Evidence of diabetic complications with significant endorgan damage History of chronic pancreatitis or at high risk for pancreatitis Poorly controlled hypertension History of cardiovascular or cerebrovascular event or procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>first in human</keyword>
	<keyword>single dose</keyword>
	<keyword>multiple dose</keyword>
	<keyword>escalation</keyword>
	<keyword>safety study</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>